This program aims to develop anti-GPC3 therapeutic CAR-T cells for immuno-oncology.
Rationale when developing the program:
For the reasons mentioned above, we believe GPC3 is a suitable target for CAR T cell therapy.
GPC3 belongs to heparin sulfate proteoglycan family, can be immobilized on the cell surface by glycosylphosphatidylinositol anchors. GPC3 can be expressed in a variety of tissues during embryonic development. Beyond that life state, it is a highly tumor-specific antigen in which expression is severely inhibited in most adult tissues.
Fig.1 Cancer immunotherapy targeting GPC3. (Shimizu, 2019)
Here are some published data about GPC3 working as a potential target for cancer immunotherapy.
(Jiang, 2019)
(Guo, 2018)
Trial | Patients | ID |
A phase I study of anti-GPC3 chimeric antigen receptor-modified T cells in Chinese patients with refractory or relapsed GPC3 + HCC | Patients with GPC3-positive HCC | NCT 02395250 |
Glypican 3-specific chimeric antigen receptor-expressing T cells as immunotherapy for patients with HCC | Patients with GPC3-positive HCC | NCT 02905188 |
Table1. Clinical trials for cancer immunotherapy targeting GPC3. (Front Oncol. 2019)
Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-GPC3 therapeutic CAR-T program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners to advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use